脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响

doi:10.3877/cma.j.issn.2095-3232.2015.04.010

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (04) : 232 -236. doi: 10.3877/cma.j.issn.2095-3232.2015.04.010

所属专题：文献；

临床研究

脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响

纪泛扑¹, 黄娜², 张澍³, 蔡芝芳⁴, 蒋安⁵, 周蕊⁵, 李宝华², 任松⁵, 李宗芳³^,^†(

)

^1. 710004　西安交通大学第二附属医院干部病房普通外科；710004　西安交通大学第二附属医院感染科
^2. 710004　西安交通大学第二附属医院生物诊断治疗国家地方联合工程研究中心
^3. 710004　西安交通大学第二附属医院干部病房普通外科；710004　西安交通大学第二附属医院生物诊断治疗国家地方联合工程研究中心
^4. 710004　西安交通大学第二附属医院感染科
^5. 710004　西安交通大学第二附属医院干部病房普通外科

收稿日期:2015-05-12 出版日期:2015-08-10
通信作者: 李宗芳
基金资助:
国家自然科学基金青年项目(81300322，30901268); 国家自然科学基金重大研究计划项目(91442122)

Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension

Fanpu Ji¹, Na Huang², Shu Zhang³, Zhifang Cai⁴, An Jiang⁵, Rui Zhou⁵, Baohua Li², Song Ren⁵, Zongfang Li³^,^†()

^1. Department of General Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China; Department of Infectious Disease, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^2. Biological Diagnosis and Treatment of National and Local Joint Engineering Research Center, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^3. Department of General Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China ; Biological Diagnosis and Treatment of National and Local Joint Engineering Research Center, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^4. Department of Infectious Disease, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
^5. Department of General Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

Received:2015-05-12 Published:2015-08-10
Corresponding author: Zongfang Li
About author:
Corresponding author: Li Zongfang, Email:lzf2568@gmail.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

纪泛扑, 黄娜, 张澍, 蔡芝芳, 蒋安, 周蕊, 李宝华, 任松, 李宗芳. 脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2015, 04(04): 232-236.

Fanpu Ji, Na Huang, Shu Zhang, Zhifang Cai, An Jiang, Rui Zhou, Baohua Li, Song Ren, Zongfang Li. Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(04): 232-236.

目的

探讨脾切除对丙型病毒性肝炎（丙肝）后肝硬化门静脉高压症患者细胞免疫功能的影响。

方法

本前瞻性研究对象为2011年12月至2013年12月在西安交通大学第二附属医院行脾切除+贲门周围血管离断术的12例丙肝后肝硬化门静脉高压症患者。其中男4例，女8例；平均年龄（55±8）岁。另选择12名健康体检者作为对照组。所有入选者均签署知情同意书，符合医学伦理学规定。观察患者术前及术后2、6周外周血NK、自然杀伤T细胞（NKT）、CD4⁺、CD8⁺ T细胞百分率及CD4⁺/CD8⁺比值的变化。手术前后不同淋巴细胞亚群的比较采用Wilcoxon秩和检验。

结果

患者术后6周CD3^-CD56⁺CD16⁺ NK细胞百分率7.7%，明显高于术前的6.2%（T=1.992，P<0.05）；术后2、6周CD56^dim NK细胞百分率分别为94.9%、96.4%，明显高于术前的87.9% （T=2.747，2.201；P<0.05）；术后2、6周CD56^bright NK细胞百分率分别为3.8%、2.4%，明显低于术前的9.2%（T=2.747，2.201；P<0.05）。术后2、6周CD3⁺CD56⁺ NKT细胞百分率分别为7.3%、7.0%，明显高于术前的6.5%（T=2.275，1.572；P<0.05）。术后2周CD4⁺ T细胞百分率为41.7%，明显低于术前的45.7%（T=3.059，P<0.05），术后6周进一步降低至26.7%（T=2.201，P<0.05）；而CD8⁺ T细胞百分率术后2周从术前的21.1%明显升高至24.8%（T=2.432，P<0.05），术后6周进一步升高至35.3%（T=1.992，P<0.05）。术前CD4⁺/CD8⁺比值为2.0，在术后2、6周明显下降至1.4、0.8（T=2.981，1.992；P<0.05）。

结论

丙肝后肝硬化门静脉高压症患者脾切除术后细胞免疫功能明显改善。

关键词: 肝硬化, 肝炎，丙型，慢性, 脾切除术, NK细胞, T淋巴细胞

Objective

To investigate the effect of splenectomy on cellular immune function of patients with hepatitis C virus (HCV) related cirrhotic portal hypertension.

Methods

Twelve patients with HCV-related cirrhotic portal hypertension undergoing splenectomy + pericardial devascularization in the Second Affiliated Hospital of Xi'an Jiaotong University between December 2011 and December 2013 were enrolled in this prospective study. Among the 12 patients, 4 were males and 8 were females with the average age of (55±8) years old. Moreover, 12 healthy people were enrolled in the control group. The informed consents of all patients were obtained and the local ethical committee approval had been received. Percentage of natural killer (NK) cell, natural killer T (NKT) cell, CD4⁺ cell, CD8⁺ T cell and CD4⁺/CD8⁺ ratio in peripheral blood before and 2, 6 weeks after splenectomy were observed. The comparison on different lymphocyte subsets was conducted using Wilcoxon rank-sum test.

Results

The percentage of CD3^-CD56⁺CD16⁺ NK cell 6 weeks after splenectomy was 7.7%, which was significantly higher than 6.2% before splenectomy (T=1.992, P<0.05). And the percentage of CD56^dim NK cell 2 and 6 weeks after splenectomy was respectively 94.9% and 96.4%, which was significantly higher than 87.9% before splenectomy (T=2.747, 2.201; P<0.05). The percentage of CD56^bright NK cell 2 and 6 weeks after splenectomy was respectively 3.8% and 2.4%, which was significantly lower than 9.2% before splenectomy (T=2.747, 2.201; P<0.05). The percentage of CD3⁺CD56⁺ NKT cell 2 and 6 weeks after splenectomy was respectively 7.3% and 7.0%, which was significantly higher than 6.5% before splenectomy (T=2.275, 1.572; P<0.05). Percentage of CD4⁺ T cell 2 weeks after splenectomy was 41.7%, which was significantly lower than 45.7% before splenectomy (T=3.059, P<0.05), and further decreased to 26.7% 6 weeks after splenectomy (T=2.201, P<0.05), while percentage of CD8⁺ T cell increased from 21.1% before splenectomy to 24.8% 2 weeks after splenectomy (T=2.432, P<0.05), and further increased to 35.3% 6 weeks after splenectomy (T=1.992, P<0.05). The CD4⁺/CD8⁺ ratio before splenectomy was 2.0 and decreased to 1.4 and 0.8 respectively 2 and 6 weeks after splenectomy (T=2.981, 1.992; P<0.05).

Conclusion

The cellular immune function of patients with HCV related cirrhotic portal hypertension after splenectomy improves significantly.

Key words: Liver cirrhotic, Hepatitis C, chronic, Splenectomy, NK cell, T lymphocytes

表1 两组术前及术后2、6周NK、NKT细胞的变化（%）

组别		例数	CD3^-CD56⁺CD16⁺ NK	CD56^dim NK	CD56^bright NK	CD3⁺CD56⁺ NKT
对照组		12	18.2(6.1～42.2)	95.8(84.6～98.6)	4.2(1.4～15.4)	4.2(1.1～13.8)
研究组		?	?	?	?	?
?	术前	12	6.2(2.6～18.7) ^a	87.9(74.4～98.7)^a	9.2(1.3～25.6)^a	6.5(3.2～12.8)
?	术后2周	12	6.9(3.1～24.5)	94.9(83.0～98.8)^b	3.8(1.2～17.0)^b	7.3(3.1～14.3)^b
?	术后6周	12	7.7(5.0～24.2)^b	96.4(90.6～98.3)^b	2.4(1.7～9.4)^b	7.0(5.4～16.4)

表1 两组术前及术后2、6周NK、NKT细胞的变化（%）

组别		例数	CD3^-CD56⁺CD16⁺ NK	CD56^dim NK	CD56^bright NK	CD3⁺CD56⁺ NKT
对照组		12	18.2(6.1～42.2)	95.8(84.6～98.6)	4.2(1.4～15.4)	4.2(1.1～13.8)
研究组		?	?	?	?	?
?	术前	12	6.2(2.6～18.7) ^a	87.9(74.4～98.7)^a	9.2(1.3～25.6)^a	6.5(3.2～12.8)
?	术后2周	12	6.9(3.1～24.5)	94.9(83.0～98.8)^b	3.8(1.2～17.0)^b	7.3(3.1～14.3)^b
?	术后6周	12	7.7(5.0～24.2)^b	96.4(90.6～98.3)^b	2.4(1.7～9.4)^b	7.0(5.4～16.4)

表2 两组术前及术后2、6周T细胞亚群的变化

组别		例数	CD4⁺ T（%）	CD8⁺ T（%）	CD4⁺/CD8⁺比值
对照组		12	36.1(28.3～59.7)	30.4(13.9～41.1)	1.2(0.9～2.2)
研究组		?	?	?	?
?	术前	12	45.7(38.4～63.7) ^a	21.1(16.6～35.6)^a	2.0(1.1～3.4)^a
?	术后2周	12	41.7(28.0～55.6) ^b	24.8(18.4～39.2)^b	1.4(0.8～3.0) ^b
?	术后6周	12	26.7(24.2～51.4) ^b	35.3(15.1～44.8) ^b	0.8(0.6～3.4) ^b

表2 两组术前及术后2、6周T细胞亚群的变化

组别		例数	CD4⁺ T（%）	CD8⁺ T（%）	CD4⁺/CD8⁺比值
对照组		12	36.1(28.3～59.7)	30.4(13.9～41.1)	1.2(0.9～2.2)
研究组		?	?	?	?
?	术前	12	45.7(38.4～63.7) ^a	21.1(16.6～35.6)^a	2.0(1.1～3.4)^a
?	术后2周	12	41.7(28.0～55.6) ^b	24.8(18.4～39.2)^b	1.4(0.8～3.0) ^b
?	术后6周	12	26.7(24.2～51.4) ^b	35.3(15.1～44.8) ^b	0.8(0.6～3.4) ^b

[1]	Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 553-562.
[2]	Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014,61 Suppl 1: S45-57.
[3]	张澍，李宗芳．脾脏功能与脾脏外科研究现状与展望[J]．中华实验外科杂志，2014, 31(2): 231-233.
[4]	Rosen HR. Emerging concepts in immunity to hepatitis C virus infection[J]. J Clin Invest, 2013, 123(10): 4121-4130.
[5]	Sugimoto K, Shiraki K. Different aspects of CD4 T cells that lead to viral clearance or persistence of HCV infection [J]. Hepatol Int, 2012, 6(1): 350-355.
[6]	Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? the example of natural killer cells[J]. Science, 2011, 331(6013): 44-49.
[7]	Jost S, Altfeld M. Control of human viral infections by natural killer cells[J]. Annu Rev Immunol, 2013(31): 163-194.
[8]	Lunemann S, Schlaphoff V, Cornberg M, et al. NK cells in hepatitis C: role in disease susceptibility and therapy[J]. Dig Dis, 2012, 30 Suppl 1: 48-54.
[9]	De Maria A, Bozzano F, Cantoni C, et al. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16⁺ NK cells as rapid producers of abundant IFN-gamma on activation[J]. Proc Natl Acad Sci U S A, 2011, 108(2): 728-732.
[10]	Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, et al. Broadly directed virus-specific CD4⁺ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence[J]. J Exp Med, 2012, 209(1): 61-75.
[11]	Hashimoto N, Shimoda S, Kawanaka H, et al. Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis[J]. Clin Exp Immunol, 2011, 165(2): 243-250.
[12]	Nomura Y, Kage M, Ogata T, et al. Influence of splenectomy in patients with liver cirrhosis and hypersplenism[J]. Hepatol Res, 2014, 44(10): E100-109.
[13]	谢玉梅，李冰，马力，等．丙型肝炎肝硬化患者脾切除或脾栓塞术后抗病毒治疗的疗效观察[J]．中华肝脏病杂志, 2012, 20(2): 112-115.
[14]	Ji F, Zhang S, Huang N, et al. Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis [J]. Braz J Infect Dis, 2013, 17(5): 601-605.
[15]	Bozzano F, Picciotto A, Costa P, et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment[J]. Eur J Immunol, 2011, 41(10): 2905-2914.
[16]	Oliviero B, Mele D, Degasperi E, et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection[J]. J Hepatol, 2013, 59(1): 38-44.
[17]	Xiao YS, Gao Q, Xu XN, et al. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection[J]. PLoS One, 2013, 8(8): e70345.
[18]	Werner JM, Heller T, Gordon AM, et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection[J]. Hepatology, 2013, 58(5): 1621-1631.

[1]	母德安, 李凯, 张志远, 张伟. 超微创器械辅助单孔腹腔镜下脾部分切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 14-14.
[2]	赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[3]	吴鹏, 许维, 王壮, 郑世海, 宋劲松. 隧道法行腹腔镜下脾切除术的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 319-322.
[4]	贺健, 张骊, 王洪海, 蒋文涛. 肝移植术后脾功能亢进转归及治疗研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 310-314.
[5]	王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[6]	蔡艺丹, 方坚, 张志强, 陈莉, 张世安, 夏磊, 阮梅, 李东良. 经颈静脉肝内门体分流术对肝硬化门脉高压患者肠道菌群及肝功能的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 285-293.
[7]	薛春娥, 赵娟娟, 刘韦成, 张义亮, 马毓晗, 李迎巧. CD4⁺CD25⁺foxp3⁺调节性T细胞通过NKG2D增强急性髓性白血病中NK细胞毒性[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(04): 212-219.
[8]	杨建辉, 段文斌, 马忠志, 卿宇豪. 腹腔镜下脾部分切除术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 314-314.
[9]	卓文锋, 曾桂芳, 杨思加, 赵家立, 邹宝嘉, 白子锐, 林恩, 李坚. 腹腔镜巨脾切除术：逐步打破的手术壁垒[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 783-788.
[10]	邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[11]	邢颖, 程石. 巨脾外科治疗现状与介入治疗序贯手术策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 253-258.
[12]	崔健, 夏青, 林云, 李光玲, 李心娜, 王位. 血小板与淋巴细胞比值、免疫球蛋白、心肌酶谱及心电图对中老年肝硬化患者病情及预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 400-406.
[13]	秦相清, 朱陈, 张海银. 构建诺模图模型预测肝硬化食管胃底静脉曲张出血的风险[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 330-335.
[14]	刘燚隆, 党荣广, 艾蓉, 张凯. 肝硬化合并静脉曲张出血患者内镜治疗后再出血风险的模型建立与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 336-342.
[15]	戚泽雪, 赵连晖, 王广川, 张春清. 从国内专家共识推荐意见更新探讨经颈静脉肝内门体分流术的临床应用进展[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(03): 193-196.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of splenectomy on cellular immune function of patients with hepatitis C virus related cirrhotic portal hypertension